05.21.14
Cincinnati, Ohio-based Devicor Medical Products Inc., a portfolio company of private equity firm GTCR, has completed the acquisition of the Hydromark breast biopsy marker portfolio and related assets from Biopsy Sciences LLC.
“We are proud to add Hydromark to our existing family of Mammotome markers,” said Devicor’ CEO Tom Daulton. “Combining Hydromark with our existing Mammomark, Mammostar and Micromark products allows us to offer customers a complete portfolio of tissue markers that meets all of their breast biopsy marking needs.”
Hydromark was developed by John Fisher, M.D., an interventional radiologist with extensive experience in breast imaging and breast biopsy. Fisher and his team developed Hydromark to provide physicians with a long-term ultrasound visible breast biopsy marking alternative. Long-term ultrasound visibility provides physicians with the option to eliminate a procedural step that can reduce the anxiety and pain of traditional breast cancer treatment.
The acquisition of Hydromark is the latest in a series of product additions by Devicor, including the addition of the Mammotome Mammotest stereotactic table, and a new distribution agreement with Faxitron on their Corevision, core specimen radiography system. These complement recent internally developed products, Mammotome revolve and Mammotome elite. Hydromark is currently available in most of North and South America, Europe and parts of Asia.
“As a company, our commitment to advancing the accurate diagnosis and treatment of breast cancer has never wavered,” said Daulton. “We continue to look for technologies that complement our flagship brand, Mammotome—the global leader in breast biopsy, as we build our innovative and market-leading organization.”
Devicor focuses on technology for the diagnosis os breast disease, such as breast cancer, through minimally invasive procedures.
“We are proud to add Hydromark to our existing family of Mammotome markers,” said Devicor’ CEO Tom Daulton. “Combining Hydromark with our existing Mammomark, Mammostar and Micromark products allows us to offer customers a complete portfolio of tissue markers that meets all of their breast biopsy marking needs.”
Hydromark was developed by John Fisher, M.D., an interventional radiologist with extensive experience in breast imaging and breast biopsy. Fisher and his team developed Hydromark to provide physicians with a long-term ultrasound visible breast biopsy marking alternative. Long-term ultrasound visibility provides physicians with the option to eliminate a procedural step that can reduce the anxiety and pain of traditional breast cancer treatment.
The acquisition of Hydromark is the latest in a series of product additions by Devicor, including the addition of the Mammotome Mammotest stereotactic table, and a new distribution agreement with Faxitron on their Corevision, core specimen radiography system. These complement recent internally developed products, Mammotome revolve and Mammotome elite. Hydromark is currently available in most of North and South America, Europe and parts of Asia.
“As a company, our commitment to advancing the accurate diagnosis and treatment of breast cancer has never wavered,” said Daulton. “We continue to look for technologies that complement our flagship brand, Mammotome—the global leader in breast biopsy, as we build our innovative and market-leading organization.”
Devicor focuses on technology for the diagnosis os breast disease, such as breast cancer, through minimally invasive procedures.